Results - Announcements
Mangalam Drugs and Organics Ltd share price gained 3.22% to Rs 30.45 after the company's net profit softened by 5.63% to Rs 7.21 crore, while revenue from operations increased sharply by 38.99% to Rs 79.39 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.82 lakh crore, gaining 5.09%. It has inched up 2.18% over last one week and crept higher by 2.72% in last one month while the market capitalization of Mangalam Drugs and Organics Ltd has marginally improved by 5.29% and 12.70% in the same period respectively.
Profit before tax (PBT) of Mangalam Drugs and Organics Ltd stood at Rs 8.99 crore in Q3 FY26, plunging by 27.91% year-on-year, and expanding by 33.19% quarter-on-quarter. EBITDA came in at Rs 1 crore, tanking 54.01% YoY and crashing by 265.00% sequentially.
Total expenses jumped by 40.40% to Rs 84.66 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 46.77 crore, surging by 39.24% YoY, while employee benefits expense was at Rs 9.33 crore, ticking higher by 4.71% YoY.
For the TTM ended FY26, revenue from operations sank 26.91% to Rs 232.13 crore, while net profit tanked by 760.71% to Rs 44.4 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 3462% to Rs 15.67 crore, and PBT tumbled by 1113.99% to Rs 48.57 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 4.18 crore in FY26, as against Rs 42.59 crore in FY25.
Mangalam Drugs and Organics Ltd nosedived by 52.25% in last one year, underperforming the benchmark BSE Sensex which has slipped by 4.80% during the same period.